# PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)

> **NCT04842331** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Thirty Respiratory Limited**

## Conditions studied

- Respiratory Viral Infection
- Respiratory Tract Diseases
- COVID-19 Respiratory Infection

## Interventions

- **DRUG:** RESP301 (a nitric oxide generating solution)
- **DRUG:** Standard of Care (SOC)

## Key facts

- **NCT ID:** NCT04842331
- **Lead sponsor:** Thirty Respiratory Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09
- **Primary completion:** 2022-01
- **Final completion:** 2022-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** A combination of factors, including the dynamic nature of the COVID-19 pandemic and the successful vaccination program, has resulted in a very sharp decline in the number of patients with COVID-19
- **Last updated:** 2024-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04842331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04842331, "PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04842331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*